Adherex Technologies Inc. (FENC) reported Q4 loss, missed revenue estimates.

From Nasdaq: 2025-03-10 07:15:02

Adherex Technologies Inc. (FENC) reported a quarterly loss of $0.06 per share, significantly lower than the expected $0.56 per share. Revenues for December 2024 were $7.93 million, missing estimates by 73.17%. The stock has gained 8.9% this year, outperforming the S&P 500. Adherex Technologies has a Zacks Rank #5 (Strong Sell).

Meanwhile, Allogene Therapeutics (ALLO) is expected to release its quarterly results on March 13. The company is projected to post a loss of $0.33 per share, with revenues expected to be $0.07 million, a 225% increase from last year. The consensus EPS estimate has remained unchanged over the past 30 days.

Investors are advised to track earnings estimate revisions and industry outlooks to make informed decisions about investing in Adherex Technologies Inc. (FENC). For more insights, Zacks Investment Research offers a free report on the 7 best stocks to buy, based on their extensive research and track record of success in the market.



Read more at Nasdaq: Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates